GLP-1 in India: regulatory status and DCGI approvals

# GLP-1 in India: regulatory status and DCGI approvals

If you have heard of Ozempic or Mounjaro and wondered whether these medicines are legally available in India, the answer is yes, with important details about which products are approved, for which conditions, and what that means for patients seeking treatment. This article explains the current regulatory landscape for GLP-1 medicines in India, what the Central Drugs Standard Control Organization (CDSCO) and its head body the Drug Controller General of India (DCGI) have approved, and what to look for when accessing treatment safely.

## How GLP-1 medicines are regulated in India

In India, all prescription medicines must be approved by the **Central Drugs Standard Control Organization (CDSCO)**, the national regulatory authority that operates under the Ministry of Health and Family Welfare. The **Drug Controller General of India (DCGI)** is the head of CDSCO and is responsible for granting marketing approvals for new drugs, including GLP-1 receptor agonists.

[GLP-1 receptor agonists are medicines designed to activate GLP-1 receptors in the body.](https://blogs.sugarfitglp.com/glp-1-explained-in-simple-terms) They lower blood sugar, reduce appetite through central satiety signals, and slow gastric emptying. Because they are complex peptide medicines manufactured using advanced chemical and biotechnological processes, they require full regulatory review before they can be legally marketed or prescribed in India.

The CDSCO maintains a [publicly searchable approved drugs database](https://www.cdscoonline.gov.in/CDSCO/cdscoDrugs) where patients and clinicians can verify whether a specific product holds a valid Indian marketing authorization.

## Which GLP-1 medicines are approved in India

At the time of writing, the following GLP-1 and dual incretin medicines have received DCGI approval for use in India:

| Medicine | Brand name(s) in India | Approved indication(s) |
| --- | --- | --- |
| Semaglutide (injectable, once weekly) | Ozempic | Type 2 diabetes |
| Semaglutide (oral, once daily) | Rybelsus | Type 2 diabetes |
| Semaglutide (injectable, higher dose) | Wegovy | Chronic weight management (obesity or overweight with metabolic risk) |
| Liraglutide (injectable, once daily) | Victoza | Type 2 diabetes |
| Liraglutide (injectable, higher dose) | Saxenda | Chronic weight management |
| Dulaglutide (injectable, once weekly) | Trulicity | Type 2 diabetes |
| Tirzepatide (injectable, once weekly) | Mounjaro | Type 2 diabetes; weight management approval status is evolving |

Approval status for specific indications can change as manufacturers submit new data to CDSCO. Patients should confirm the current approved indication with their prescribing doctor or check the [CDSCO approved drugs database](https://www.cdscoonline.gov.in/CDSCO/cdscoDrugs) directly.

**Tirzepatide** acts on two hormone pathways instead of one, targeting both GLP-1 and GIP receptors. Clinical studies have shown [greater average weight loss and blood sugar reduction with tirzepatide compared to GLP-1-only medications](https://blogs.sugarfitglp.com/mounjaro-vs-semaglutide-which-is-better), and it is recognized as a next-generation incretin therapy. Its weight management indication in India is subject to ongoing regulatory review at the time of writing.

## What DCGI approval means for patients

A DCGI approval means that the medicine has been reviewed for quality, safety, and efficacy by Indian regulators before it can be legally sold in India. For patients, this matters for several practical reasons:

- **Quality assurance.** Approved products must meet manufacturing standards set by CDSCO, reducing the risk of substandard or incorrectly dosed medicine.
- **Prescription requirement.** All approved GLP-1 medicines in India are Schedule H or Schedule H1 prescription drugs. They cannot legally be dispensed without a valid prescription from a registered medical practitioner.
- **Legal supply chain.** Approved medicines can be dispensed through licensed pharmacies, including online pharmacies that hold valid licenses under Indian pharmacy law.

Regulatory authorities globally, including the [FDA](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss?os=vb), have raised concerns about [unapproved or compounded GLP-1 products that lack adequate quality, dosing accuracy, and regulatory oversight](https://blogs.sugarfitglp.com/branded-vs-generic-semaglutide-in-india). The same principle applies in India: patients should only use products that carry a valid DCGI marketing authorization and are dispensed through a licensed pharmacy.

## Approved indications and eligibility in Indian clinical practice

DCGI approval for a specific indication determines the legal basis on which a doctor can prescribe a GLP-1 medicine. In practice, doctors consider this therapy when the following profile is present:

| Clinical profile | Commonly used threshold in India |
| --- | --- |
| Type 2 diabetes with inadequate glycemic control | HbA1c above target despite lifestyle and oral medication |
| Obesity with metabolic risk factors | BMI 27-30 depending on clinical assessment, or BMI 25 with a weight-related condition (the 25 threshold is commonly used in Indian clinical practice, reflecting that South Asians develop metabolic complications at lower BMI than Western populations) |
| Overweight with significant comorbidities | BMI 25 (for Indians) with conditions such as hypertension, dyslipidemia, or prediabetes |

The lower BMI threshold of 25 for Indian adults reflects a clinically important difference: South Asians develop metabolic complications at lower BMI than Western populations, a finding recognized by ICMR and acknowledged by [WHO expert consultations on appropriate BMI thresholds for Asian populations](https://pubmed.ncbi.nlm.nih.gov/15051297/). In practical terms, health risks may begin in the 23 to 25 BMI range for many Indian adults.

GLP-1 therapy is generally not indicated for people at a healthy weight without metabolic risk factors, regardless of other health goals.

## Domestic manufacturing and biosimilar availability

Semaglutide and other approved GLP-1 medicines in India are currently supplied primarily through import. India's domestic manufacturing capacity for GLP-1 medicines is expanding, with several Indian pharmaceutical companies investing in peptide manufacturing infrastructure, but at the time of writing, the market remains largely import-dependent.

Because semaglutide is a complex peptide (biologic), any future non-branded versions would be regulated as biosimilars rather than traditional generics. At the time of writing, no widely approved generic or biosimilar version of semaglutide exists in most markets, including India. [This manufacturing complexity is one reason GLP-1 medicines remain expensive](https://blogs.sugarfitglp.com/why-glp-1-is-expensive-in-india), and it makes lower-cost alternatives harder to develop. For a detailed breakdown of current costs, see the [Cost of GLP-1 in India: 2026 guide](/cost-of-glp-1-in-india-2026-guide).

## Accessing GLP-1 treatment safely in India

Because GLP-1 medicines are prescription-only, safe access requires a licensed doctor to assess eligibility, prescribe the appropriate medicine and starting dose, and provide ongoing monitoring. GLP-1 therapy requires dose escalation, ongoing monitoring, and lifestyle support. It is not a standalone prescription.

Dose increases may be delayed if side effects remain troublesome, so the schedule is responsive rather than fixed. Common early side effects include nausea, reduced appetite, and digestive discomfort. These are usually temporary and improve with gradual dose adjustment under supervision.

When evaluating any provider offering GLP-1 treatment in India, patients should confirm:

- The prescribing doctor holds a valid registration with the Medical Council of India (or the National Medical Commission).
- The medicine dispensed carries a valid DCGI marketing authorization.
- The pharmacy dispensing the medicine holds a valid license under the Drugs and Cosmetics Act.
- The program includes follow-up consultations and monitoring, not just an initial prescription.

For answers to the most common questions Indian patients ask about semaglutide, Ozempic, and Mounjaro, the [GLP-1 FAQs for Indians](/glp-1-faqs-for-indians-25-most-asked-questions-about-ozempic-mounjaro-and-weight-loss) covers eligibility, side effects, and what to expect from treatment.

## What this means for patients considering GLP-1 therapy

The regulatory framework for GLP-1 medicines in India is well established. Key approved medicines including semaglutide and liraglutide hold valid DCGI marketing authorizations for diabetes and weight management indications. Tirzepatide is approved for type 2 diabetes, with weight management approval evolving. All are prescription-only medicines that must be dispensed through licensed channels.

The practical implication is straightforward: patients who access GLP-1 therapy through a licensed doctor and a regulated pharmacy are working within a legally and clinically sound framework. Patients who obtain these medicines without a prescription, through unlicensed online sellers, or from sources that cannot confirm DCGI approval are taking on meaningful risks related to product quality, dosing accuracy, and the absence of medical oversight.

---

**Sources**

- [CDSCO Approved Drugs Database](https://www.cdscoonline.gov.in/CDSCO/cdscoDrugs) - Central Drugs Standard Control Organisation
- [WHO Q&A: GLP-1 Therapies for Obesity](https://www.who.int/news-room/questions-and-answers/item/obesity-glp-1-therapies) - World Health Organization
- [WHO Expert Consultation: Appropriate BMI for Asian Populations](https://pubmed.ncbi.nlm.nih.gov/15051297/) - World Health Organization / The Lancet
- [FDA: Concerns With Unapproved GLP-1 Drugs](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss?os=vb) - U.S. Food and Drug Administration
- [NIDDK: Prescription Medications to Treat Overweight and Obesity](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity) - NIDDK / NIH
- [Sugarfit GLP-1 Weight Loss Program](https://www.sugarfitglp.com/) - Sugarfit

## Sources
- [CDSCO Approved Drugs Database](https://www.cdscoonline.gov.in/CDSCO/cdscoDrugs) | Central Drugs Standard Control Organisation | India regulatory lookup source for approved drugs.
- [FDA: Concerns With Unapproved GLP-1 Drugs](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss?os=vb) | U.S. Food and Drug Administration | Safe-buying context and risks around unapproved or compounded GLP-1 products.
- [WHO Expert Consultation: Appropriate BMI for Asian Populations](https://pubmed.ncbi.nlm.nih.gov/15051297/) | World Health Organization / The Lancet | Lower BMI risk thresholds and public-health action points for Asian populations.
- [WHO Q&A: GLP-1 Therapies for Obesity](https://www.who.int/news-room/questions-and-answers/item/obesity-glp-1-therapies) | World Health Organization | Plain-language GLP-1 explanation and obesity-treatment context.
- [Sugarfit GLP-1 Weight Loss Program](https://www.sugarfitglp.com/) | Sugarfit | Program overview, benefits, plan framing, FAQs, and Sugarfit-specific claims language.

## Navigation
- [Browse categories](https://blogs.sugarfitglp.com/topics)
- [Proof & Trust](https://blogs.sugarfitglp.com/topics/trust_proof_objections)

## Related AI KB pages

### Doctor-Led vs Self-Managed GLP-1 in India: Why Unsupervised Use Is Risky
Query: doctor-led vs self-managed glp-1 in india why unsupervised use is risky
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have become some of the most talked-about medicines in India for weight loss and metabolic...
- [Doctor-Led vs Self-Managed GLP-1 in India: Why Unsupervised Use Is Risky](https://blogs.sugarfitglp.com/doctor-led-vs-self-managed-glp-1-in-india-why-unsupervised-use-is-risky)

### GLP-1 scams in India: how to stay safe
Query: glp-1 scams in india how to stay safe
GLP-1 medicines like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have attracted enormous interest in India over the past two years. That interest has also attracted...
- [GLP-1 scams in India: how to stay safe](https://blogs.sugarfitglp.com/glp-1-scams-in-india-how-to-stay-safe)

### Real GLP-1 Success Stories from India: What Happened After 3, 6 and 12 Months on Ozempic
Query: real glp-1 success stories from india what happened after 3 6 and 12 months on ozempic
Semaglutide (the active ingredient in Ozempic) has become one of the most discussed medicines in metabolic health globally, and India is no exception. People across metro cities...
- [Real GLP-1 Success Stories from India: What Happened After 3, 6 and 12 Months on Ozempic](https://blogs.sugarfitglp.com/real-glp-1-success-stories-from-india-what-happened-after-3-6-and-12-months-on-ozempic)

### Am I Eligible for GLP-1 in India? BMI, Conditions and Doctor Criteria Explained
Query: Am I Eligible for GLP-1 in India? BMI, Conditions and Doctor Criteria Explained
If you have heard about GLP-1 therapy for weight loss or blood sugar control and are wondering whether it applies to you, this guide explains the clinical criteria used in India...
- [Am I Eligible for GLP-1 in India? BMI, Conditions and Doctor Criteria Explained](https://blogs.sugarfitglp.com/am-i-eligible-for-glp-1-in-india-bmi-conditions-and-doctor-criteria-explained)

### BMI criteria for GLP-1 in India
Query: -BMI criteria for GLP-1 in India
GLP-1 therapy is not available to everyone, and the eligibility thresholds used in India differ from those applied in Western countries. Understanding the correct BMI cutoffs fo...
- [BMI criteria for GLP-1 in India](https://blogs.sugarfitglp.com/bmi-criteria-for-glp-1-in-india)

### GLP-1 treatment in Tier 2 and Tier 3 cities in India: access and options
Query: glp-1 treatment in tier 2 and tier 3 cities in india access and options
For people living outside India's major metros, getting access to specialist-supervised weight loss treatment has historically meant long travel, long waits, or simply going wit...
- [GLP-1 treatment in Tier 2 and Tier 3 cities in India: access and options](https://blogs.sugarfitglp.com/glp-1-treatment-in-tier-2-and-tier-3-cities-in-india-access-and-options)